Shengyin Biotech

Shengyin Biotech is a clinical-stage biopharmaceutical company based in Suzhou, China, focused on the discovery and development of innovative RNA interference (RNAi) therapeutics. The company utilizes its proprietary LEAD (Liver-targeted Efficient siRNA Delivery) platform to develop a robust pipeline of small interfering RNA (siRNA) drugs targeting metabolic and cardiovascular diseases. Its lead candidate, SNB-001, is an siRNA targeting ANGPTL3 for the treatment of hypertriglyceridemia, while SNB-002 targets AGT for hypertension. Founded by industry veterans with extensive experience in nucleic acid drugs, Shengyin Biotech is positioned to address global unmet medical needs through long-acting, highly specific genetic medicines. The company has successfully raised significant venture capital from top-tier investors to advance its clinical programs and expand its technology platform.